Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
Neurocrine Biosciences (NASDAQ: NBIX) announced survey findings highlighting the need for enhanced education on managing tardive dyskinesia (TD) symptoms. The data, presented at the MDS International Congress from September 15-18, 2022, in Madrid, revealed that the prevalence of TD is often underestimated. Key findings include an increase in clinicians opting for pharmacologic therapies and acknowledging patient complaints regarding social anxiety. The company emphasizes the importance of managing TD while addressing underlying psychiatric disorders.
- None.
- None.
SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder. These results (abstract #29) will be shared at the MDS International Congress of Parkinson's Disease and Movement Disorders® September 15-18 in Madrid, Spain.
The case-based survey assessed practice, knowledge, and attitudes of psychiatrists and neurologists, including a subset of movement disorder specialists in the U.S., in managing of patients with TD across 3 timepoints (N=400 in May 2018, N=253 in March 2020, and N=202 in December 2021). Results demonstrate that:
- The prevalence of TD continues to be underestimated
- Over time, more respondents are considering pharmacologic therapy as initial management for patients with TD and opting for a VMAT2 inhibitor to manage TD movements
- The most common patient complaints prompting treatment for TD were patient embarrassment/social anxiety and effect on quality of life
- The most significant perceived barrier to optimal management of TD continues to be apprehension of losing control of the patient's underlying psychiatric symptoms
"These survey findings demonstrate the continued importance of education for clinicians in the proactive screening, recognition, and treatment of TD as standard of care for at-risk populations," said Eiry W. Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. "Management of TD in conjunction with maintaining control of the underlying psychiatric disorder is of key importance. Neurocrine Biosciences is committed to furthering education on supportive evidence regarding pharmacologic approaches to the treatment of TD."
A full list of abstracts being presented by Neurocrine Biosciences at MDS International Congress of Parkinson's Disease and Movement Disorders® is available on the meeting website.
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (like antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as depression, bipolar disorder, schizophrenia and schizoaffective disorder, and certain medications to treat upset stomach, nausea and vomiting are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the U.S.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid- to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter and Facebook. (*in collaboration with AbbVie).
The Neurocrine logo is a registered trademark of Neurocrine Biosciences, Inc.
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from the Company's products, the Company's plans to advance education that may help address the needs of people living with TD, and the value that such education may bring to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the commercialization of the Company's products; risks that the Company's products may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects or adverse reactions; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions; whether the survey findings represent the experiences of people living with TD; whether the Company can successfully advance the education that may help address the unmet needs of people living with TD; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2022. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.
©2022 Neurocrine Biosciences, Inc. All Rights Reserved. 09/2022
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-study-findings-on-evolving-tardive-dyskinesia-education-needs-of-physicians-at-the-2022-mds-international-congress-301624811.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
What is the focus of Neurocrine Biosciences' recent survey on tardive dyskinesia?
When and where did Neurocrine present their survey findings?
What were the key findings from Neurocrine's survey on tardive dyskinesia?
What is tardive dyskinesia, and how many people does it affect in the U.S.?
How does Neurocrine Biosciences aim to address the needs of patients with tardive dyskinesia?
